Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.76 |
---|---|
High | 10.40 |
Low | 9.76 |
Bid | 10.02 |
Offer | 10.44 |
Previous close | 10.36 |
Average volume | -- |
---|---|
Shares outstanding | 67.66m |
Free float | 43.02m |
P/E (TTM) | -- |
Market cap | 3.86m CHF |
EPS (TTM) | -0.3597 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼
Announcements
- Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
- Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
- Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiotix, Inc.